Abstract
Atrial fibrillation (AF) is the most common arrhythmia worldwide with treatments such as anticoagulants, rate control, and catheter ablation only aiming to reduce complications. Ischemic preconditioning (IPC), defined as brief cycles of ischemia followed by reperfusion, has emerged as a promising cardioprotective strategy. This review aims to provide a comprehensive review on and discuss recent trials surrounding the use of ischemic preconditioning as a promising therapeutic alternative in the treatment of atrial fibrillation. Clinical trials in both surgical and interventional settings have shown encouraging evidence that these protective mechanisms can lead to meaningful reductions in atrial arrhythmia. Despite these encouraging findings, heterogeneity persists likely due to differences in patient selection, anesthetic regimens, and the timing or protocols of preconditioning. The collective evidence highlights the therapeutic potential surrounding the use of ischemic preconditioning in atrial fibrillation. With recent trials on the rise, IPC's potential impact on rhythm control, pharmacologic responsiveness, cardioversion outcomes, and complication rates is highly promising for the treatment of atrial fibrillation. Further research is required to translate these findings into routine clinical practice, particularly in high-risk populations such as those with concurrent heart failure or structural heart disease.